A new study published in ERJ Open Research highlights promising results for IKOMED’s ATMOS radiofrequency (RF) device, a non-invasive therapy for emphysema. Conducted in collaboration with researchers at St. Paul’s Hospital Centre for Heart and Lung Innovation in Vancouver and the UBC Centre for Comparative Medicine, the study represents an important step toward clinical translation of IKOMED’s extracorporeal RF technology.
The research demonstrated that a single RF treatment can significantly reduce emphysema severity with no serious adverse effects. Analysis of treated tissue showed meaningful improvements in lung structure, building on earlier studies that indicated improved lung mechanics and function following RF therapy.
Lung volume reduction surgery remains the only proven option for advanced emphysema but carries substantial risks and costs. IKOMED’s ATMOS RF treatment aims to offer a safer, non-surgical alternative by selectively targeting diseased tissue externally.
These results mark a major milestone in the development of a novel, non-invasive therapy for patients with emphysema.
View the full article here.
